CXCL16. a member of the CXC chemokine family, exists in both soluble and transmembrane forms. The transmembrane isoform functions as a scavenger receptor for oxidized low-density lipoprotein (oxLDL) and mediates cell adhesion, while the soluble form, generated via proteolytic cleavage by disintegrin and metalloproteinases (ADAMs), acts as a chemoattractant for CXCR6-expressing immune cells, such as T cells and natural killer (NK) cells. CXCL16 plays dual roles in inflammation and homeostasis, participating in immune surveillance, leukocyte trafficking, and lipid metabolism.
CXCL16 antibodies are essential tools for studying its expression, localization, and function in physiological and pathological contexts. They enable detection of CXCL16 in tissues (e.g., by immunohistochemistry) or biological fluids (e.g., by ELISA) and are used to block CXCL16-CXCR6 interactions in functional assays. Dysregulation of CXCL16 is implicated in diseases like atherosclerosis, rheumatoid arthritis, and cancer. In cancer, CXCL16 may promote tumor progression by recruiting immunosuppressive cells or inducing angiogenesis, making it a potential therapeutic target.
Research utilizing CXCL16 antibodies has highlighted its role as a biomarker in cardiovascular diseases and autoimmune disorders. Neutralizing antibodies are being explored to inhibit pro-inflammatory or pro-tumorigenic signaling pathways. However, the pleiotropic nature of CXCL16 necessitates careful evaluation of therapeutic strategies to avoid disrupting its homeostatic functions.